IL-18 BINDING MOLECULES

IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 recepto...

Full description

Saved in:
Bibliographic Details
Main Authors SCHLAEPPI, Jean-Marc Alfred, DIEFENBACH-STREIBER, Beate, KUNZ, Christian Carsten Silvester, MARSHALL, Sylwia, CAMPBELL, Emma Michelle, VAN HEEKE, Gino Anselmus, BARDROFF, Michael Otto, BRANNETTI, Barbara, EBERTH, Adina, RONDEAU, Jean-Michel Rene
Format Patent
LanguageEnglish
French
German
Published 21.10.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
Bibliography:Application Number: EP20200157418